Takeda: ‘Reducing Hypertension Spend in … PCT’ mailing found to be disguised promotion (AUTH/1978/3/07)

📊

Key facts

⌄

Case number	AUTH/1978/3/07
Complainant	Primary care trust assistant director, medicines management
Company	Takeda UK Ltd
Material	Mailing/leaflet: ‘Reducing Hypertension Spend in … PCT’ / ‘Reducing Hypertension Management Spend in … PCT’
Product	Amias (candesartan)
Main issue	Unclear source; misleading impression of PCT endorsement; disguised promotion
Applicable Code year	2006
Breach clauses	Clauses 7.2 and 10.1
Sanction	Undertaking received
Complaint received	18 March 2007 (also reported as 19 March 2007 in the report text)
Case completed	14 May 2007 (also reported as 15 May 2007 in the report text)
Appeal	No appeal

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

📋

⌄

A PCT assistant director (medicines management) complained about a Takeda mailing titled ‘Reducing Hypertension Spend in … PCT’ promoting Amias (candesartan) via local cost-saving messages.
The leaflet was sent to each GP in the PCT in a plain envelope, with no cover note and no clear identification of the author/source on the front or within the main content.
The leaflet repeatedly referenced the PCT (about ten times) and presented itself as a local financial review and strategy to reduce hypertension prescribing spend.
GPs contacted the complainant asking whether the leaflet had been officially endorsed by the PCT, as it appeared to be.
Takeda argued it was a corporate/clinical style, not intended to mimic NHS/PCT materials, and that inclusion of prescribing information showed it was promotional.

⚖️

⌄

The Panel ruled the source of the leaflet was not sufficiently clear and that it gave the impression it was something other than company promotional material.
The Panel found the material was misleading and constituted disguised promotion.
Breach rulings: Clauses 7.2 and 10.1.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access